MondegarAI
Commodore Capital LP

Q2 2024 · 13F-HR

Commodore Capital LPholdings as filed

Filed 2024-08-14 · accession 0001880562-24-000002

$1.47B
Reported value
35
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
N5749R1002GHMERUS N V$189.3M12.9%3,200,000CommonSOLE
670703107NUVLNUVALENT INC$112.9M7.70%1,487,756CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$107.4M7.33%2,754,266CommonSOLE
92243G108PCVXVAXCYTE INC$98.5M6.73%1,305,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$92.9M6.34%3,973,245CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$89.5M6.11%2,475,000CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$82.1M5.60%9,738,000CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$58.1M3.97%1,425,000CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$52.7M3.60%1,425,000CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$51.5M3.52%7,145,888CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$50.3M3.43%1,225,000CommonSOLE
04335A105ARVNARVINAS INC$50.2M3.42%1,884,361CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$46.7M3.19%1,988,084CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$46.4M3.17%4,657,345CommonSOLE
N69605108PHVSPHARVARIS N V$34.0M2.32%1,810,175CommonSOLE
G01767105ALKSALKERMES PLC$33.1M2.26%1,375,000CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$32.9M2.25%2,528,032CommonSOLE
50127T109KURAKURA ONCOLOGY INC$32.8M2.24%1,593,350CommonSOLE
65487U108NKTXNKARTA INC$24.5M1.67%4,151,034CommonSOLE
15102K100CELCCELCUITY INC$24.0M1.64%1,464,105CommonSOLE
88427A107THIRD HARMONIC BIO INC$20.1M1.37%1,545,426CommonSOLE
45258J102IMVTIMMUNOVANT INC$19.8M1.35%750,990CommonSOLE
00370M103ABVXABIVAX SA$17.0M1.16%1,284,110CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$16.9M1.16%825,000CommonSOLE
12529R107CCCCC4 THERAPEUTICS INC$15.8M1.08%3,410,384CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$14.1M0.97%2,000,000CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$11.4M0.78%290,000CommonSOLE
12674W109CABACABALETTA BIO INC$8.2M0.56%1,100,000CommonSOLE
G70077105PCSCPERCEPTIVE CAP SOLUTIONS COR$7.5M0.52%750,000CommonSOLE
64135M105NGNENEUROGENE INC$7.3M0.50%200,000CommonSOLE
92840H400VTGNVISTAGEN THERAPEUTICS INC$5.5M0.37%1,575,000CommonSOLE
G4444H101BBOTHELIX ACQUISITION CORP II$5.1M0.35%500,000CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$4.1M0.28%1,178,723CommonSOLE
00211Y506ABIOEURARCA BIOPHARMA INC$1.6M0.11%414,325CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$498,8000.03%40,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.